Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
Aytu BioPharma to present at Lytham Partners Fall 2023 Investor Conference
10/09/2023 - 04:15 PM
ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.
Company Webcast
The Company's webcast presentation will be available for viewing at 7:00am ET on Tuesday, October 17, 2023, on the Company's website at https://investors.aytubio.com/ or https://wsw.com/webcast/lytham9/aytu/2072440 . The webcast will also be archived and available for replay.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at https://www.lythampartners.com/fall2023invreg/ .
About Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu's consumer health segment markets a range of over-the-counter medicines and consumer health products addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions. To learn more, please visit aytubio.com .
Contacts for Investors: moki@aytubio.com
Robert Blum or Roger WeissAYTU@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
https://www.accesswire.com/790894/aytu-biopharma-to-present-at-lytham-partners-fall-2023-investor-conference-on-october-17-2023
What event is Aytu BioPharma participating in?
Aytu BioPharma is participating in the Lytham Partners Fall 2023 Investor Conference.
When is the webcast presentation available?
The webcast presentation will be available for viewing at 7:00am ET on Tuesday, October 17, 2023.
How can I watch the webcast presentation?
The webcast presentation can be viewed on Aytu BioPharma's website or the following link: https://wsw.com/webcast/lytham9/aytu/2072440.
Can I arrange a meeting with Aytu BioPharma's management?
Yes, you can arrange a meeting with management by contacting Lytham Partners at 1x1@lythampartners.com or registering at https://www.lythampartners.com/fall2023invreg/.
AYTU Rankings
#3164 Ranked by Stock Gains
AYTU Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Consumer Services, Other Consumer Services, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Loveland
About AYTU
aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.
